The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
As an initial remote monitoring diagnostic approach, Philips BioTel Heart MCOT detected 4.6 times more patients with atrial fibrillation compared to implantable loop recorder alone
The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform
The approval now covers procedures using 10-14F inner diameter and up to 17F outer diameter procedural sheaths
Researchers say simple blood-test and echocardiography pathway could reshape diabetes-related cardiovascular care
71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
Subscribe To Our Newsletter & Stay Updated
